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INTRODUCTION:  Occasionally,  lymph  node  metastases  represent  the  only  component  at the  time  of  recur-
rence of  ovarian  cancer.  Here  we  report  the  case  of a  78-year-old  Japanese  female  who  underwent
successful  surgery  for recurrent  ovarian  cancer  with  multiple  lymph  node  metastases.
PRESENTATION  OF  CASE:  The patient  was referred  to  our  institution  with  recurrent  disease  accompanied
by  chemoresistant  multiple  retroperitoneal  lymph  node  metastases  ﬁve  years  after  the initial  therapy
for stage  IIIc  serous  adenocarcinoma  of  the  ovary.  Positron  emission  tomography/computed  tomography
(PET/CT)  revealed  the involvement  of  two para-aortic  nodes  and  two pelvic  nodes,  with  no  other  posi-
tive  site.  The  patient  underwent  systematic  para-aortic  and  pelvic  lymphadenectomy,  and the  metastatic
nodes  were  completely  resected.  Histopathological  examination  revealed  metastatic  high-grade  adeno-
carcinoma  in four of 63  dissected  lymph  node  specimens.  The  patient  has  been  in clinical  remission  for
over  four  years  without  any  further  additional  therapies.
DISCUSSION:  In our case,  the  metastatic  nodes  predicted  by PET/CT  completely  corresponded  to the  actual
metastatic  nodes;  however,  PET/CT  often  fails to identify  microscopic  disease  in pathological  positive
nodes.  We  cannot  reliably  predict  whether  lymph  node  metastasis  will  persist  in the  limited  range.
Therefore,  systematic  lymphadenectomy  with  therapeutic  intent  should  be performed,  although  it  does
not always  mean  that  we remove  all cancer  cells.
CONCLUSION:  The  ﬁndings  from  this  case  suggest  that,  even  if used  as  secondary  cytoreductive  surgery
in  the context  of  a recurrent  disease,  systematic  aortic  and  pelvic  node  dissection  might  sometimes
contribute  to the  control  if  not  cure  of  ovarian  cancer.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
The majority of patients with ovarian cancer are diagnosed at
dvanced stages, and this form of cancer is considered to be the
ost lethal gynecological cancer. At least 50% patients ultimately
evelop recurrent disease and succumb, despite achieving clinical
emission after completion of initial treatment.1 The most com-
on  site for recurrence of ovarian cancer is the intraperitoneal
avity. Occasionally, however, lymph node metastases represent
he predominant or only component at the time of recurrence. The
ationale for extensive aortic and pelvic node dissection is based on
he observation that the rate of lymph node metastases at surgery
fter chemotherapy is similar to or only modestly lower than that
t initial surgery, indicating that nodal disease is less curable by
hemotherapy compared with disease at other sites.2,3 Here we
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http://creativecommons.org/licenses/by-nc-nd/3.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
report the case of a 78-year-old Japanese who underwent success-
ful surgery for recurrent ovarian cancer with multiple lymph node
metastases and has been alive with no evidence of disease for more
than four years thereafter.
2. Presentation of case
A 73-year-old Japanese female was  diagnosed with advanced
ovarian cancer at a cancer center in Tokyo. After neoadjuvant
chemotherapy with one cycle of paclitaxel plus carboplatin and
one cycle of docetaxel (converted from paclitaxel because of hyper-
sensitivity to paclitaxel) plus carboplatin, she had undergone an
interval cytoreductive surgery consisting of hysterectomy, bilat-
eral salpingo-oophorectomy, partial omentectomy, and peritoneal
stripping. The surgery was considered optimal according to the
intraoperative ﬁndings (i.e., the size of intraperitoneal residual
tumors was less than 1 cm in diameter), although lymph nodes
were not dissected. Histopathologically, the tumor was a high-
grade serous adenocarcinoma (Stage IIIc, pT3cNxM0). Following six
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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ycles of adjuvant chemotherapy of docetaxel plus carboplatin, she
chieved a complete clinical response. Thereafter, she was  admin-
stered oral etoposide and carboplatin sequentially for 11 months
s maintenance chemotherapy.
Twenty-seven months after the initial treatment was  started
22 months after the initial treatment was completed), she expe-
ienced the ﬁrst relapse, which was diagnosed by examining
levated serum CA125 levels and computer tomography (CT)
mages of enlarged para-aortic nodes (PANs). She received one
ycle of docetaxel plus carboplatin and three cycles of second-
ine chemotherapy with gemcitabine plus carboplatin (converted
rom the prior regimen because of adverse effects from docetaxel).
ecause she had experienced a hypersensitivity reaction with car-
oplatin in the third cycle of the regimen and had achieved clinical
emission, she was followed without any further treatment.
The second relapse was noted 11 months after the ﬁrst, with
he same relapse site diagnosed by CT images. She received nine
ycles of third-line chemotherapy with irinotecan plus cisplatin
or 11 months. Although the tumors initially decreased in size,
hey subsequently stopped shrinking. Thereafter, although she was
dministered oral etoposide for four months, PAN and pelvic lymph
ode size increased and serum CA125 levels elevated gradually. The
atient was persuaded that the best supportive care was  the only
emaining option. However she wished to explore the possibility of
ny further treatment. Sixty-two months after the ﬁrst treatment
nitiation, she was referred to our institution with a seven months
herapy-free interval.
Her Eastern Cooperative Oncology Group (ECOG) performance
tatus was 1 without any complaints, although she suffered from
ild hypertension and took medication for the same. Her labo-
atory data were within normal limits, except that serum CA125
evels increased to 104.5 U/ml.
Positron emission tomography/computed tomography (PET/CT)
evealed the involvement of two PANs (31 mm × 25 mm
nd 24 mm × 18 mm,  respectively) and two  pelvic nodes
38 mm × 45 mm and 13 mm  × 16 mm,  respectively), and there
as no other positive site (Fig. 1). Contrast-enhanced CT clearly
dentiﬁed these enlarged nodes, which we considered to be
esectable (Fig. 2). After providing written informed consent, she
nderwent systematic PAN and pelvic lymphadenectomy. The
etroperitoneal metastatic nodes were completely resected in
he absence of signiﬁcant adhesion to the vessels during surgery
surgical duration: 324 min, blood loss: 930 g [Fig. 3]). Histopatho-
ogically, we conﬁrmed metastatic high-grade adenocarcinomas in
our of 63 dissected lymph node specimens, which were identical
o the nodes detected on PET/CT and CT (Fig. 4). Macroscopi-
ally, there was no intraperitoneal disease. Peritoneal cytology
as negative. Despite thrombo-prophylaxis with intermittent
neumatic compression of the legs and subcutaneous crude
eparin administration was employed, on postoperative day two,
Fig. 2. Enhanced computed tomography (CT) images clearly shows enlarged nodFig. 1. Positron emission tomography shows four positive lymph nodes, but no other
positive sites.
she experienced mild pulmonary embolism, which ameliorated,
without any adverse events, after anticoagulation therapy with
intravenous heparin and, subsequently, oral warfarin. She dis-
charged on postoperative day 25. We  refrained from performing
any adjuvant therapy after SDS, because the patient preferred
a follow-up regimen with no further intervention. She is being
followed-up at our outpatient clinic and has been in good health
with no evidence of disease for over 50 months after surgery.
3. Discussion
Although primary cytoreductive surgery is well accepted as
the cornerstone of initial management, the role of cytoreductive
surgery in the setting of recurrent disease remains controversial.
Several retrospective studies have demonstrated a beneﬁt of sec-
ondary cytoreductive surgery (SCS) and identiﬁed the prognostic
factors for survival in these patients, including performance status,
es. (A) Precaval and lateroaortic nodes. (B) Bilateral suprainguinal nodes.
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Fig. 3. Images of lymph node dissection (2) corresponds to the precaval node, (3) corres
(1)  The right suprainguinal node is not indicated here. Abbreviations: RCILA, right commo
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our patient experienced pulmonary embolism postoperatively. Toig. 4. Macroscopic appearance of dissected lymph nodes. Microscopically, four
1–4) out of 63 dissected lymph nodes were positive for metastatic adenocarcinoma.
isease-free interval, number of recurrent tumors, maximum
ize of tumors, presence of liver metastases, and presence of
arcinomatosis.4–6
According to these prognostic factors, selection criteria or guide-
ines for SCS have been proposed. For instance, Chi et al. proposed
 recommendation for SCS on the basis of disease-free interval,
umber of recurrence sites, and evidence of carcinomatosis.6 Our
atient fulﬁlled their criteria: no carcinomatosis despite the pres-
nce of multiple recurrence sites, and a disease-free interval of
ore than 12 months. Meanwhile, Bristow et al. reviewed 40 cohort
tudies of patients undergoing surgical intervention for recurrent
varian cancer (2019 patients).7 They concluded that only that
roportion of patients undergoing complete cytoreduction is inde-
endently associated with overall post-recurrence survival time.
anici et al. evaluated the role of systematic lymphadenectomy in
varian cancer patients with recurrent bulky lymph node disease.8ponds to the lateroaortic node, and (4) corresponds to the left suprainguinal node.
n iliac artery; LEILA, left external iliac artery.
They concluded that these patients could beneﬁt from systematic
lymphadenectomy in terms of survival, although all 29 patients
had received postoperative adjuvant treatment. To achieve com-
plete cytoreduction of tumor, systematic lymphadenectomy with
therapeutic intent (not a diagnostic one) should be performed
as described in the textbook by Morrow and Curtin.9 Even so,
removing all the lymph nodes that we  can reach or ﬁnd does
not always mean that we remove all cancer cells. We occasion-
ally experience recurrent ovarian cancer patients with lymph node
metastases spread to multiple sites. In our patient, the metastatic
nodes predicted by PET/CT completely corresponded to the actual
metastatic nodes. In general, when conventional CT ﬁndings are
negative or equivocal, PET/CT demonstrates high sensitivity and
a positive predictive value in identifying recurrent ovarian cancer
in retroperitoneal lymph nodes. Bristow et al., however, reported
that PET/CT failed to identify microscopic disease in nearly 60%
of pathological positive nodes.10 Thus, we  cannot reliably predict
whether lymph node metastasis will persist in the limited range.
One hypothesis is that a relatively slow increase in the serum CA
125 level during a treatment-free period, as in our case, may  be
one sign of possible complete cytoreduction of a tumor, because it
may suggest that the tumor is in a dormant state. Further cohort
studies with large sample size would be warranted to address these
issues.
Even with the above-mentioned limitation, we have several
criteria that need to be fulﬁlled before considering retroperitoneal
lymphadenectomy as SCS for patients with recurrent ovarian can-
cer. First, lymph nodes metastasis should be at least assessed with
PET/CT and contrast-enhanced CT to conﬁne within the resectable
area, without any other recurrent lesions. Second, the lesions
should be surgery- and irradiation-naive, regardless of the number
of metastases. The disease-free interval and the ECOG performance
status of patients should also be considered. Although not so severe,avoid severe complications, preoperative assessment of risks for
them and perioperative management should be taken meticu-
lously.
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. Conclusion
We  experienced the case of a Japanese female who under-
ent successful surgery for recurrent ovarian cancer with multiple
ymph node metastases. Retrospectively, there may  have been no
ecurrence in the patient if systematic lymphadenectomy had been
erformed during the initial surgery. This is just a case report
nd we cannot make general conclusions. However, our ﬁndings
uggest that systematic aortic and pelvic node dissection might
ometimes contribute to the control if not cure of ovarian cancer,
ven if used as SCS in the context of a recurrent disease. Physicians
hould not abandon any possibility to control a cancer as long as
he patient chooses to do so.
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Key learning points
• Even if used in the context of a recurrent disease, systematic lymphadenectomy with therapeutic intent might some-
times contribute to the control if not cure of ovarian cancer.
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